Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

India’s Dr Reddy’s to buy some UCB brands for $128 mln

April 2, 2015
Life sciences
(Reuters) – India’s second-largest drugmaker by sales, Dr Reddy’s Laboratories Ltd, will buy some established brands of Belgian drugmaker UCB SA in South Asia for 8 billion rupees ($128.38 million), the company said on Wednesday.
 
As competition heats up, Indian drugmakers are looking to strengthen existing porfolios in fast-growing emerging markets, as well as at home.
 
The country’s largest drugmaker, Sun Pharmaceutical Industries Ltd, closed a deal to buy rival Ranbaxy Laboratories Ltd last month, strengthening its presence, particularly in emerging markets.
 
Dr Reddy’s said the acquisition of brands in India, Nepal, Sri Lanka and the Maldives, would help it win a bigger foothold in the areas of respiratory, dermatology and pediatrics drugs.
 
The acquired business generated revenue of about 1.5 billion rupees in 2014, Dr Reddy’s said.
 
The India part of the business employs about 350 people.
 
Some brokerege analysts, however, expressed concern about the acquisition cost, with the deal valuing the UCB business more than five times its sales, which, they said, was higher than the industry standard.
 
“You would demand this kind of valuation when you’re buying the leader in the industry. And I’m not sure if Dr Reddy’s has got leading brands from UCB,” said Nimish Mehta of Equirus Securities.
 
UCB Chief Operating Officer Mark McDade said in a statement the deal would allow the Belgian company to sharpen its focus on its neurology portfolio in India. Dr Reddy’s said it expected to close the deal in the first quarter of this financial year.
 
Last month, Reuters reported that Dr Reddy’s was in talks with UCB for a deal concerning the latter’s Indian operations, citing a source with direct knowledge of the matter. ($1=62.3150 Indian rupees) (Reporting by Zeba Siddiqui in Mumbai; Editing by Clarence Fernandez; Editing by Sumeet Chatterjee and Clarence Fernandez)

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach